How Full-Spectrum CBDa Oil Offers Hope for Rare Blood Disease (ET)
How Full-Spectrum CBDa Oil Offers Hope for Rare Blood Disease (ET)
A remarkable patient story that even surprised doctors – and why Peter Vermeul's research is receiving increasing attention
Much is happening in the world of medicinal cannabis—but every now and then, a research paper appears that has the potential to shift the field. The latest article by Peter Vermeul , founder of CBD Spain and a pioneer in full-spectrum CBD extracts, is just such a publication.
On the CBD & Herb science page, we compile all his research articles, but this particular piece stands out. Not only because it describes a rare blood disorder, but especially because one patient—Daniel from the United States—experienced a development that even his specialist had never observed before.
What is Essential Thrombocythemia (ET)?
Essential thrombocythemia (ET) is a rare myeloproliferative neoplasm (MPN) in which the bone marrow produces too many platelets. These platelets normally play an important role in blood clotting.
However, at ET this excess can lead to:
-
dangerous blood clots
-
increased risk of bleeding
-
risk of strokes and heart problems
-
long-term chronic stress on the body
Only 1 in 100,000 people worldwide develop ET. The disease is chronic and currently incurable. Treatment focuses primarily on reducing risk and managing symptoms.
Diagnosis and medical treatment: often lifelong
ET is diagnosed through a combination of blood tests, genetic testing (including JAK2, CALR, and MPL mutations), and bone marrow examination.
Common treatments include:
-
Aspirin , to prevent clots
-
Hydroxyurea , chemotherapy to reduce platelets
-
Anagrelide , to reduce the risk of strokes
-
Interferon alpha , inhibits abnormal cell division
-
Ruxolitinib , for patients who do not respond to other agents
Yet, regulating platelets often remains complex — and that's where Daniel's story becomes interesting.
Daniel's Story: 14 Years of ET – Until Something Unexpected Happened
Daniel, a 64-year-old man from the US, has been living with ET for 14 years . In all those years, his platelet count has never dropped below 600,000 . The medically normal range is between 150,000 and 450,000 .
Between 2017 and 2023, Daniel's blood sugar levels fluctuated around an average of 689,500 — and remained consistently elevated until the end of 2023 despite medication.
Until he started using a Full-Spectrum CBDa oil from CBD Spain on June 6, 2024, rich in natural cannabinoid acids, terpenes, flavonoids and the rare Cannflavines A, B and C.
His daily intake: 3 drops 3 times a day .
What happened next surprised everyone — especially his doctor
-
After 5 days of use → platelets dropped to 560,000
Below 600,000 for the first time in 14 years -
After 60 days → further decline to 528,000
A total decrease of 25%
His specialist said he'd never seen this in an ET patient before. Daniel himself was also astonished and hopeful. He's eagerly awaiting his upcoming checkups.
Why this oil is so special: Cannflavins A, B and C
Unlike many CBD products on the market, CBD Spain extracts consist of all-natural, unprocessed plant components , including the rare Cannflavins .
Cannflavines:
-
are found exclusively in cannabis
-
are powerful anti-inflammatories
-
play a role in the regulation of platelets
-
are preserved in their natural ratio in Full-Spectrum extracts
That's why these extracts are of interest for medical and scientific applications. Peter Vermeul has been researching these substances for years and documenting his findings—as in the article on which this blog post is based.
Why This Research Story Is Relevant for Anyone Using CBD
While this research makes no medical claim and further scientific evidence is needed, Daniel's experience raises new questions for both doctors and patients:
-
What is the role of cannabinoid acids in chronic blood diseases?
-
How exactly do Cannflavins work within the body?
-
And can Full-Spectrum CBDa provide support in regulating blood levels?
It is precisely these questions that drive Peter Vermeul to further research, document and share via our science page.
Read the full research by Peter Vermeul
Would you like to read the full background, sources, graphs and the complete patient story?
On our science page you will find the complete article by Peter Vermeul, including all references to medical literature